Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Next Previous
X
Search
Drug Profile

Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Alternative Names: GS 9857/sofosbuvir/velpatasvir; GS-5816/GS-9857/sofosbuvir; GS-7977/GS-5816/GS-9857; GS-9857/GS-5816/sofosbuvir; GS-9857/SOF/VEL; GS-9857/VEL/SOF; GS-9857/velpatasvir/sofosbuvir; SOF/GS-9857/VEL; SOF/VEL/GS-9857; SOF/VEL/VOX; Sofosbuvir/GS-5816/GS-9857; Sofosbuvir/GS-9857/velpatasvir; Sofosbuvir/velpatasvir/GS-9857; Sofosbuvir/voxilaprevir/velpatasvir; VEL/GS-9857/SOF; VEL/SOF/GS-9857; Velpatasvir/GS-9857/sofosbuvir; Velpatasvir/sofosbuvir/GS-9857; Velpatasvir/sofosbuvir/voxilaprevir; Velpatasvir/voxilaprevir/sofosbuvir; Vosevi; Voxilaprevir/sofosbuvir/velpatasvir; Voxilaprevir/velpatasvir/sofosbuvir

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 28 Sep 2022 Sofosbuvir/velpatasvir/voxilaprevir is still in phase III trial for Hepatitis C (Treatment-naïve, Treatment-experienced) in South Korea (PO) (NCT04211909)
  • 28 Sep 2022 No development reported - Phase-II for Hepatitis C (In adolescents, In children) in Italy, Germany, United Kingdom, Poland (PO) (NCT03820258)
  • 31 Dec 2020 Gilead Sciences has patent protection for sofosbuvir/velpatasvir/voxilaprevirin in USA and EU

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top